From: Usage of compromised lung volume in monitoring steroid therapy on severe COVID-19
Outcome | Stage 2 | Stage 3 | Stage 4 | Stage 5 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Changes in quantitative CT parameters (%) | Coefficient | 95% CI | P value | Coefficient | 95% CI | P value | Coefficient | 95% CI | P value | Coefficient | 95% CI | P value |
Changes in CL a |  − 2.02 |  − 4.55 to 0.51 | 0.12 |  − 3.73 |  − 7.18 to − 0.29 | 0.03 |  − 3.95 |  − 7.57 to − 0.33 | 0.03 |  − 5.01 |  − 8.95 to − 1.08 | 0.01 |
Changes in NNL b |  − 0.23 |  − 1.49 to 1.02 | 0.71 |  − 0.83 |  − 2.34 to 0.68 | 0.28 |  − 1.15 |  − 2.99 to 0.69 | 0.22 |  − 1.07 |  − 3.06 to 0.92 | 0.28 |
Changes in PAL c |  − 1.01 |  − 2.74 to 0.72 | 0.25 |  − 2.31 |  − 4.71 to 0.08 | 0.06 |  − 1.85 |  − 4.10 to 0.40 | 0.11 |  − 2.99 |  − 5.24 to − 0.75 | 0.01 |
Changes in NAL d | 3.65 | 0.68 to 6.63 | 0.02 | 8.23 | 4.50 to 11.96 |  < 0.01 | 7.82 | 3.41 to 12.23 |  < 0.01 | 9.59 | 4.65 to 14.53 |  < 0.01 |
Changes in HI e |  − 2.54 |  − 5.96 to 0.88 | 0.14 |  − 2.73 |  − 6.91 to 1.45 | 0.20 |  − 1.77 |  − 7.01 to 3.47 | 0.50 |  − 3.27 |  − 8.67to 2.12 | 0.23 |